Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
RSS SUMMARY · AGGREGATED FROM TWSJ
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Sports
Four High Schools in Four Years: The Wild World of Athlete Transfers in Florida
TWSJ·1h ago·3 min read
Business
Five Questions to Help You Make Better Financial Decisions
TWSJ·3h ago·3 min read
World News
Israel Built and Defended a Secret Iran War Base in Iraq
TWSJ·8h ago·3 min read
Tech
For Palantir, AI Is a Product, a Punching Bag—and a Problem
TWSJ·10h ago·3 min read
Related
On this beat
Business
Fidelity lays out the playbook of successful investors
THE STREET·2h ago·3 min read
Business
Jim Cramer makes a bold call on AI as stocks waver
THE STREET·3h ago·3 min read
Business
Uber’s CEO doesn’t have a perfect 5-star rider rating
BI·2h ago·3 min read
Business
Five Questions to Help You Make Better Financial Decisions
TWSJ·3h ago·3 min read